Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

Inclusion Criteria: * Aged≥18 and \<75 years. * Histologically or cytologic confirmed Non-small cell lung cancer, Phase IIIB or IV according to UICC 2017. * ECOG performance status of 0 to 1. * Life expectancy of more than 3 months. * Confirmed HER2 mutation and amplification by Central Laboratory. Direct sequencing (RT-PCR or ARMS-PCR) or second generation sequencing (NGS) was used for HER2 mutation, and fluorescence in situ hybridization (FISH) or ngs was used for HER2 amplification; * At least one RECIST 1.1 defined measurable lesions. * Patients who had not received systemic treatment for advanced / metastatic NSCLC in the past but had disease progression more than 12 months after receiving neoadjuvant therapy or the last use of adjuvant therapy could be enrolled. * Required laboratory values including following parameters:ANC≥1.5×109/L,Platelet count≥90×109/L,Hemoglobin≥90 g/L;Total bilirubin:≤ 1.5×upper limit of normal, ULN, ALT and AST≤ 2.0×ULN; BUN and Cr: ≤1.5 x ULN;creatine clearance rate: ≥ 50 mL/min, LVEF: ≥ 50%; QTcF:\< 470 ms for female and \< 450 ms for male. * Signed informed consent. Exclusion Criteria: * Previous therapy with other HER2 inhibitors. * Inability to swallow、chronic diarrhea and intestinal obstruction that affect the drug taking and absorption. * There is unstable third space effusion (such as large amount of pleural effusion and ascites). * Received radiotherapy, chemotherapy, surgery or other targeted therapy for non-small cell lung adenoca…